FSFilippo Scalise

Filippo Scalise

*This is an algorithmically generated author record based on publicly available information.

Filippo Scalise has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pathophysiology of Hypertension in Chronic Kidney Disease: Role of the Sympathetic Nervous System Activation

    by Filippo Scalise, Evelina Toscano, Antonio Sorropago, Chiara Amman, Guido Grassi

  • Assessment of the Safety and Effectiveness of the FLOWer Antiembolic Filter Supporting Transcatheter Aortic Valve Implantation

    by Antonio Sorropago, Federico De Marco, Evelina Toscano, Nedy Brambilla, Matteo Montorfano, Eugenio Stabile, Elvin Kedhi, Pierfrancesco Agostoni, Marco Gennari, Paolo Vitali, et al.

    Background: Embolic events are life‐threatening complications of transcatheter aortic valve implantation (TAVI) with clinically relevant stroke rates of 2%–4%. Aims: This study aims to evaluate the safety and effectiveness of FLOWer, a novel embolic protection device (EPD) used in TAVI procedures. Methods: Data on the FLOWer device were obtained from its CE‐mark clinical trial (the NAUTILUS study, NCT 04704258). Safety outcomes were the 30‐day rate of major adverse events (MAEs, including all deaths, ischemic strokes, and acute kidney injury), while effectiveness data consisted of the number of particles captured by the filter during the procedure. These data were compared with benchmark values from the EPD literature. In addition, the total number (TNL) and volume (TVL) of new brain lesions were evaluated. Results: A total of 52 intention‐to‐treat (ITT) patients were considered, 45 of whom were per protocol (PP) patients. The rate of 30‐day MAEs for the PP population was 2.2% (1/45% vs. 14.3%, p = 0.0082); no strokes were observed. The median number of captured debris larger than 60 μm was 213 (IQR: 128−315 vs. 46.1, p < 0.0001), and larger than 150 μm, 105 (IQR: 60−190 vs. 41.6, p < 0.0001). The median TVL and TNL per patient were 291.7 mm 3 (IQR: 98.5−630.7 mm 3 ) and 4.5 mm 3 (IQR: 2.0−8.3 mm 3 ), respectively. Conclusions: The use of FLOWer during TAVI was found to be feasible and safe, with a low incidence of MAEs and a reduced number and volume of new brain lesions. The significant amount of debris captured compared to similar devices demonstrates effective device performance.


  • Open Access

    Comparison Between Invasive and Noninvasive Methods to Estimate Subendocardial Oxygen Supply and Demand Imbalance

    by Paolo Salvi, Corrado Baldi, Filippo Scalise, Andrea Grillo, Lucia Salvi, Isabella Tan, Lorenzo De Censi, Antonio Sorropago, Francesco Moretti, Giovanni Sorropago, et al.

    Background: Estimation of the balance between subendocardial oxygen supply and demand could be a useful parameter to assess the risk of myocardial ischemia. Evaluation of the subendocardial viability ratio (SEVR, also known as Buckberg index) by invasive recording of left ventricular and aortic pressure curves represents a valid method to estimate the degree of myocardial perfusion relative to left ventricular workload. However, routine clinical use of this parameter requires its noninvasive estimation and the demonstration of its reliability. Methods and Results: Arterial applanation tonometry allows a noninvasive estimation of SEVR as the ratio of the areas directly beneath the central aortic pressure curves obtained during diastole (myocardial oxygen supply) and during systole (myocardial oxygen demand). However, this “traditional” method does not account for the intra‐ventricular diastolic pressure and proper allocation to systole and diastole of left ventricular isometric contraction and relaxation, respectively, resulting in an overestimation of the SEVR values. These issues are considered in the novel method for SEVR assessment tested in this study. SEVR values estimated with carotid tonometry by "traditional” and "new” method were compared with those evaluated invasively by cardiac catheterization. The “traditional” method provided significantly higher SEVR values than the reference invasive SEVR: average of differences±SD= 44±11% (limits of agreement: 23% – 65%). The noninvasive “new” method showed a much better agreement with the invasive determination of SEVR: average of differences±SD= 0±8% (limits of agreement: ‐15% to 16%). Conclusions: Carotid applanation tonometry provides valid noninvasive SEVR values only when all the main factors determining myocardial supply and demand flow are considered.


  • Heart rate variability, postural sway and electrodermal activity in competitive golf putting

    by Filippo Scalise, Davide Margonato, Alessandro Frigerio, Roberto Zappa, Raffaele Romano, Egidio Beretta

    BACKGROUND: Stressful conditions during competitive golf putting may result in impaired performance, producing physiological changes. Nevertheless, simultaneous measurements of postural sway (PS), heart rate variability (HRV) and electrodermal activity (EDA) during a competitive golf putting have not yet been examined. This study aims at describing if changes in PS, HRV and EDA during golf putting, might affect the golfer's performance. METHODS: Based on EGA-handicap, 40 amateur golfers were divided in 2 groups. They competed in an indoor round of golf putting. PS, EDA, HRV and putting performance (SCORE) were recorded at basal and during competition. RESULTS: During the putting round, a significant increase in low-frequency power (LF) and decrease in high-frequency power (HF) was found in Group A, leading to an increased LF/HF ratio. The heart rate increased significantly more in Group A than in Group B, but the stress index (SI) remained lower in this group. EDA significantly increased in both groups, with no statistical difference between groups. No statistical difference in SCORE was observed. CONCLUSIONS: Despite the significant differences observed between the two groups, both at baseline and in response to competition, no variation of the studied variables was associated with a better putting performance.


  • Ambulatory blood pressure monitoring by a novel cuffless device: a pilot study

    by Filippo Scalise, Davide Margonato, Andrea Sole, Antonio Sorropago, Giovanni Sorropago, Giuseppe Mancia

    Purpose: Cuffless blood pressure (CL-BP) measurements are believed to be a potentially alternative to cuff-occlusion-based (C-BP) measurement. A new cuffless device was developed for ambulatory BP monitoring. We assessed the accuracy of a new CL-BP device compared to a standard oscillatory C-BP device over the 24 h. Materials and methods: Eighty-four consecutive patients were included in the study. BP was measured simultaneously by the CL-BP device and by a C-BP device over the 24 h. Calculations included 24 h mean systolic (S) BP, the mean diastolic (D) BP and the heart rate (HR). Correlations between the CL-BP and C-BP measurements were sought using Pearson’s correlation coefficients and Bland-Altman plots. Results: Using the C-BP device, the 24 h SBP value for the cohort was 125.4 ± 10.9 mmHg (mean ± SD); the corresponding DBP value being 75 ± 8.3 mmHg. Mean SBP/DBP were higher with the CL-BP device, i.e. 131.1 ± 15.9/80.2 ± 9.7 mmHg . The correlation coefficients between the two sets of values were significant (SBP: r = 0.58, DBP: r = 0.65). Better correlations for SBP and DBP were found 1) in patients with BMI > 25 (SBP: r = 0.65, DBP: r = 0.70) compared to those with BMI r = 0.71, DBP: r = 0.77). Conclusions: In our patients a CL-BP device estimated 24 h mean SBP and DBP differently from the classical oscillometric device, with a moderate correlation. CL-BP measurements were most accurate on male and overweight subjects.


  • Hypertension in aortic stenosis: a focused review and recommendations for clinical practice

    by Sahrai Saeed, Filippo Scalise, John B. Chambers, Giuseppe Mancia

    In patients with aortic stenosis, the presence of hypertension negatively affects the hemodynamic severity of the stenosis, and worsens adverse left ventricular remodeling. It accelerates the progression of the stenosis and is associated with worse prognosis. Proper management of hypertension is thus crucial but there are concerns about the safety and efficacy of antihypertensive medications as well as uncertainty about optimal blood pressure (BP) targets and their impact on left ventricular mass regression and survival benefits. In the present review, we discuss these issues based on the evidence available in the current literature. Focus is first directed on the consequences of a persistently elevated BP before and after surgical aortic valve replacement or transcatheter valve implantation, and the clinical significance of an abnormal BP response during exercise in patients with significant aortic stenosis. Available data on use of antihypertensive drugs are then critically addressed, the conclusion being that calcium channel blockers may be associated with lower survival, and that diuretics may have disadvantages in patients with left ventricular hypertrophy and smaller left ventricular cavity dimensions, β-blockers may be well tolerated and a better choice for patients with concomitant coronary artery disease and arrhythmias. Renin--angiotensin system blockers improve survival given either before or after valve intervention. Emphasis is placed on the fact that evidence is not derived from randomized trials but only from observational studies. Finally, we discuss the optimal SBP level to reach in patients with aortic stenosis. Again, randomized trials are not available but observational evidence suggests that values between 130 and 139 mmHg systolic and 70–90 mmHg diastolic might represent the best option, and lower BP targets should probably be avoided.


  • A new Percutaneous technique for effective vascular Access Site closure in patients undergoing Transfemoral aortic valve implantation and thoraco-abdominal aortic aneurysm rEpair: the PASTE study

    by Giovanni Sorropago, Gurbhej Singh, Antonio Sorropago, Andrea Sole, Jessica Rossi, Valerio Stefano Tolva, Eugenio Stabile, Filippo Scalise

    Aims: The success of transfemoral transcatheter aortic valve implantation (TAVI) and thoraco-abdominal aneurysm repair (TAAR) depends on haemostatic control of the access site, which is usually obtained with suture-based closure devices (Prostar or two ProGlide). A single ProGlide/Glubran technique, involving a suture placement on the vessel wall followed by tissue glue injection around the vessel wall, has not been previously investigated in this clinical setting. Our aim was to study the feasibility and safety of a single ProGlide/Glubran technique for vascular access-site closure after transfemoral TAVI and TAAR. Methods and results: This technique was used in 250 patients from 2012 to 2017. The primary endpoint was the success of the technique, defined as access-site haemostasis without complications and not requiring any additional intervention within 30 days of the index procedure. Patients had a mean age of 82.4 +/- 1.93 years, with a logistic EuroSCORE of 20.2 +/- 2.32. A total of 218 TAVI and 32 TAAR procedures were performed with a mean sheath size of 18.09 +/- 1.55 Fr. The mean sheath to femoral artery ratio was 1.04 +/- 0.16, with mean femoral artery minimal lumen diameter 6.65 +/- 0.64 mm. The overall success rate of this technique was 98.4%. Four patients (1.6%) developed critical stenosis of the femoral artery requiring balloon dilatation. No major VARC-2 vascular complications were observed. Thirty-day mortality was 0.4% (non-cardiovascular). Conclusions: The results of this study suggest that the single ProGlide/Glubran technique is a safe and effective method of closing the arterial access site after transfemoral TAVI and TAAR. The results of our study need to be confirmed in a randomised controlled trial before being adopted in routine clinical practice.


  • Open Access

    Carbon dioxide coronary angiography: A mechanical feasibility study with a cardiovascular simulator

    by Ivan Corazza, Nevio Taglieri, Edoardo Pirazzini, Pier Luca Rossi, Alessandro Lombi, Filippo Scalise, James G. Caridi, Romano Zannoli

    The aim of this study was to carry out a bench evaluation of the biomechanical feasibility of carbon dioxide (CO2) coronary arteriography. Many patients among the aging population of individuals requiring cardiac intervention have underlying renal insufficiency making them susceptible to contrast-induced nephropathy. To include those patients, it is imperative to find an alternative and safe technique to perform coronary imaging on cardiac ischemic patients. As CO2 angiography has no renal toxicity, it may be a possible solution offering good imaging with negligible collateral effects. Theoretically, by carefully controlling the gas injection process, new automatic injectors may avoid gas reflux into the aorta and possible cerebral damage. A feasibility study is mandatory. A mechanical mock of the coronary circulation was developed and employed. CO2 was injected into the coronary ostium with 2 catheters (2F and 6F) and optical images of bubbles flowing inside the vessels at different injection pressures were recorded. The gas behavior was then carefully studied for quantitative and qualitative analysis. Video recordings showed that CO2 injection at a precise pressure in the interval between the arterial dicrotic notch and the minimum diastolic value does not result in gas reflow into the aorta. Gas reflow was easier to control with the smaller catheter, but the gas bubbles were smaller with different vascular filling. Our simulation demonstrates that carefully selected injection parameters allow CO2 coronary imaging without any risk of gas reflux into the aorta.


  • Long‐Term Contrast Echocardiography and Clinical Follow‐Up after Percutaneous Closure of Patent Foramen Ovale Using Two Different Atrial Septal Occluder Devices

    by Filippo Scalise, Carla Auguadro, Giovanni Sorropago, Antonio Sorropago, Eugenio Novelli, Marica Finizio, Giuseppe Specchia

    Introduction: Percutaneous patent foramen ovale (PFO) closure by means of a septal occluder device (SOD) is a well‐known therapeutic strategy for the secondary prevention of paradoxical embolic neurological events. The aim of this study was to provide long‐term echocardiographic and clinical follow‐up data on patients who had undergone percutaneous PFO closure with 2 different SOD.Methods: We selected 2 groups of patients treated with 2 different SOD: Group A: 52 patients with an Amplatzer® PFO Occluder and Group B: 49 patients with a Figulla Flex® device. All patients underwent follow‐up Bubble Test Transthoracic Echocardiography (BTTE) and clinical examination. The results were compared with those recently reported in a group of patients with similar characteristics, but that had been treated conservatively, which acted as a control group.Results: The mean follow‐up after PFO closure was 53 months. The Amplatzer® PFO Occluder and the Figulla Flex were used in 52 (51.5%) and 49 (48.5%) of patients, respectively. We found no significant difference in the rate of effective PFO closure between the devices: Amplatzer 91.4%, Figulla 93.9% (P = 0.71). One patient (1.0%) suffered a recurrent neurologic event. BTTE was positive (BTTE+) in 8 patients (8%), 5 with an Amplatzer, and 3 with a Figulla device (P = 0.516). Only 1 patient with BTTE+ had a recurrent TIA (12.5%). No significant relationship was found between device dimensions and BTTE+ (P = 0.062). In the control group (163 patients), the recurrence of neurologic events was 9.2% (15 events), that was significantly higher in respect to the patients who had undergone percutaneous closure of the PFO.Conclusions: Percutaneous PFO closure was associated with a remarkably low risk of recurrent embolic neurological events, and no long‐term device‐related major complications. No statistically significant difference emerged between the 2 different SODs regarding BTTE positivity. Long‐term follow‐up showed that the recurrence of neurological events has been significantly higher in the group treated in a conservative way.